


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A PYY agonist derivative of the formula:



wherein X is a ~~radical~~ 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenyl-methoxycarbonyl (FMS), Z is the residue of a PYY agonist linked to the radical X through an amino or hydroxyl group, and n is 1 to 3, or a pharmaceutically acceptable salt thereof.

2. (currently amended) A PYY agonist derivative of claim 1, wherein the PYY agonist is PYY of the sequence represented by {SEQ ID NO.: 1}:

YPIKPEAPGEDASPEELNRYIASLRHYLNLVTRQRY-NH₂.

3. (currently amended) A PYY agonist derivative of claim 1, wherein the PYY agonist is PYY₃₋₃₆ of the sequence represented by †SEQ ID NO.: 2†:

IKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-NH₂.

4. (original) The PYY agonist derivative of claim 1 selected from the group consisting of the derivatives herein designated Fmoc-PYY, (Fmoc)₂-PYY, (Fmoc)₃-PYY, FMS-PYY, (FMS)₂-PYY and (FMS)₃-PYY.

5. (original) The PYY agonist derivative of claim 1 selected from the group consisting of the derivatives herein designated Fmoc-PYY₃₋₃₆, (Fmoc)₂-PYY₃₋₃₆, (Fmoc)₃-PYY₃₋₃₆, FMS-PYY₃₋₃₆, (FMS)₂-PYY₃₋₃₆, and (FMS)₃-PYY₃₋₃₆.

6. (currently amended) The PYY agonist derivative herein designated (FMS)₂-PYY₃₋₃₆, of the sequence represented by †SEQ ID NO.: 3†.

7. (currently amended) A pharmaceutical composition comprising a PYY agonist derivative according to ~~any one of~~ ~~claims claim 1 to 6~~, and a pharmaceutically acceptable carrier.

8. (original) A pharmaceutical composition comprising (FMS)₂-PYY₃₋₃₆ and a pharmaceutically acceptable carrier.

Claims 9-16 (Cancelled)

17. (original) A method for reduction of food intake which comprises administering to an individual in need an effective amount of a PYY agonist derivative of claim 1.

18. (original) A method for treatment of a disease, condition or disorder that can be alleviated by reduction of food intake which comprises administering to an individual in need an effective amount of a PYY agonist derivative of claim 1.

19. (currently amended) The method according to claim ~~14~~ 18 wherein said disease or disorder is obesity.

20. (currently amended) The method according to claim ~~14~~ 18 wherein said disease or disorder is hypertension, dyslipidemia, cardiovascular risk, eating disorder, insulin-resistance, or diabetes mellitus.

21. (original) A method of treating obesity in an individual comprising administering to said individual a therapeutically effective amount of $(FMS)_2$ -PYY₃₋₃₆, or a pharmaceutically acceptable salt thereof.

22. (original) A method of inducing weight loss in an individual comprising administering to said individual a therapeutically effective amount of a PYY agonist derivative of claim 1 or a pharmaceutically acceptable salt of said compound.

23. (currently amended) A method according to claim 22 ~~of inducing weight loss in an individual comprising~~

In re of: RUBINSTEIN10A

~~administering to said individual a therapeutically effective
amount of~~ wherein said PYY agonist derivative is

(FMS)₂-PYY₃₋₃₆, or a pharmaceutically acceptable salt thereof.